Hepatocellular carcinoma secondary prevention: Difference between revisions
Mahshid |
m Bot: Removing from Primary care |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{MJK}} | {{CMG}} {{AE}} {{MJK}} | ||
==Overview== | ==Overview== | ||
Secondary prevention strategies following hepatocellular carcinoma include [[retinoids]], Intra-arterial iodine-131-lipiodol embolization, and adoptive adjuvant immunotherapy. | |||
==Secondary Prevention== | |||
Secondary prevention strategies following hepatocellular carcinoma include [[retinoids]], Intra-arterial iodine-131-lipiodol embolization, and adoptive adjuvant immunotherapy.<ref name="pmid15918144">{{cite journal| author=Colombo M, Donato MF| title=Prevention of hepatocellular carcinoma. | journal=Semin Liver Dis | year= 2005 | volume= 25 | issue= 2 | pages= 155-61 | pmid=15918144 | doi=10.1055/s-2005-871195 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15918144 }} </ref> | Secondary prevention strategies following hepatocellular carcinoma include [[retinoids]], Intra-arterial iodine-131-lipiodol embolization, and adoptive adjuvant immunotherapy.<ref name="pmid15918144">{{cite journal| author=Colombo M, Donato MF| title=Prevention of hepatocellular carcinoma. | journal=Semin Liver Dis | year= 2005 | volume= 25 | issue= 2 | pages= 155-61 | pmid=15918144 | doi=10.1055/s-2005-871195 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15918144 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Needs content]] | |||
[[Category:Disease]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Types of cancer]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
[[Category:Emergency medicine]] | |||
Latest revision as of 22:08, 29 July 2020
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma secondary prevention |
|
Risk calculators and risk factors for Hepatocellular carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Secondary prevention strategies following hepatocellular carcinoma include retinoids, Intra-arterial iodine-131-lipiodol embolization, and adoptive adjuvant immunotherapy.
Secondary Prevention
Secondary prevention strategies following hepatocellular carcinoma include retinoids, Intra-arterial iodine-131-lipiodol embolization, and adoptive adjuvant immunotherapy.[1]
References
- ↑ Colombo M, Donato MF (2005). "Prevention of hepatocellular carcinoma". Semin Liver Dis. 25 (2): 155–61. doi:10.1055/s-2005-871195. PMID 15918144.